GlassScriptPhysician profile
Sally M Khalifa
NPI 1427430487
$1,124.26
in general payments reported to CMS, 2019-2025
14 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.70 · 2023: $284 · 2024: $297 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $253.20 | 2023-2025 | |
| Lilly USA, LLC | $235.77 | 2023-2025 | Mounjaro, Emgality, Zepbound |
| Novo Nordisk INC | $199.70 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $87.09 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $70.41 | 2023-2025 | |
| Glaxosmithkline, LLC. | $61.68 | 2023-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $51.26 | 2023-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.49 | 2022-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $33.36 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.34 | 2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $21.17 | 2024 | Gemtesa |
| Axsome Therapeutics, INC. | $17.81 | 2025 | Symbravo |
| Nevro Corp. | $17.57 | 2023 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.41 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Khalifa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.